BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 26200823)

  • 1. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
    Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
    Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Mora PAR; Sun SY; Velarde GC; Filho JR; Uberti EH; Dos Santos Esteves APV; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2019 May; 153(2):277-285. PubMed ID: 30857648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial.
    Lertkhachonsuk AA; Israngura N; Wilailak S; Tangtrakul S
    Int J Gynecol Cancer; 2009 Jul; 19(5):985-8. PubMed ID: 19574798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Lawrie TA; Alazzam M; Tidy J; Hancock BW; Osborne R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD007102. PubMed ID: 27281496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Cost-Effectiveness Between Actinomycin D Versus Methotrexate-Folinic Acid in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Lertkhachonsuk AA; Hanvoravongchai P
    J Reprod Med; 2016; 61(5-6):230-4. PubMed ID: 27424364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
    Miller CR; Chappell NP; Sledge C; Leath CA; Phippen NT; Havrilesky LJ; Barnett JC
    Gynecol Oncol; 2017 Jan; 144(1):125-129. PubMed ID: 27816248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
    Li J; Li S; Yu H; Wang J; Xu C; Lu X
    Gynecol Oncol; 2018 Feb; 148(2):247-253. PubMed ID: 29203174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line chemotherapy in low-risk gestational trophoblastic neoplasia.
    Alazzam M; Tidy J; Hancock BW; Osborne R; Lawrie TA
    Cochrane Database Syst Rev; 2012 Jul; 7(7):CD007102. PubMed ID: 22786502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folinic acid rescue during methotrexate treatment for low-risk gestational trophoblastic neoplasia - How much is just right?
    Poli JG; Paiva G; Freitas F; Mora P; Velarde LGC; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
    Gynecol Oncol; 2021 Sep; 162(3):638-644. PubMed ID: 34266689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of treatment for low-risk GTN with standard 8-day MTX/FA regimen versus modified MTX/FA regimen without chemotherapy on the weekend.
    Braga A; de Souza Hartung Araújo C; Mora PAR; Paulino E; de Melo AC; Velarde GC; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
    Gynecol Oncol; 2020 Mar; 156(3):598-605. PubMed ID: 31928806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acid.
    Taylor F; Grew T; Everard J; Ellis L; Winter MC; Tidy J; Hancock BW; Coleman RE
    Eur J Cancer; 2013 Oct; 49(15):3184-90. PubMed ID: 23870384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-Day Intravascular Methotrexate Versus Biweekly Actinomycin-D in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial.
    Yarandi F; Mousavi A; Abbaslu F; Aminimoghaddam S; Nekuie S; Adabi K; Hanjani P
    Int J Gynecol Cancer; 2016 Jun; 26(5):971-6. PubMed ID: 27101581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jun; 117(3):477-80. PubMed ID: 20347479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors related to treatment outcomes in low-risk gestational neoplasia.
    Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
    Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia.
    Shah NT; Barroilhet L; Berkowitz RS; Goldstein DP; Horowitz N
    J Reprod Med; 2012; 57(5-6):211-8. PubMed ID: 22696815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flat-dose versus weight or body surface area-based methotrexate dosing in low-risk gestational trophoblastic neoplasia.
    Parker VL; Cushen BF; Hills A; Kandiah K; Palmer JE; Singh K; Hancock BW; Tidy JA; Winter MC
    Gynecol Oncol; 2023 Feb; 169():34-40. PubMed ID: 36495594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical epidemiology and management of gestational trophoblastic neoplasia in Hungary in the past 34 years.
    Fülöp V; Szigetvári I; Szepesi J; Végh G; Singh M; Berkowitz RS
    J Reprod Med; 2012; 57(7-8):310-8. PubMed ID: 22838247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing and evaluating the efficacy of methotrexate and actinomycin D as first-line single chemotherapy agents in low risk gestational trophoblastic disease.
    Lee YJ; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    J Gynecol Oncol; 2017 Mar; 28(2):e8. PubMed ID: 27819410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of MACT and 5Fu+ACT-D chemotherapy regimens in the treatment of low-risk gestational trophoblastic neoplasia.
    Wang Y; Miao JW; Wang T; Wang Y; Wu YM; Kong WM; Su L; Duan W
    J Chemother; 2016 Apr; 28(2):135-9. PubMed ID: 27105436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.